Project Grant R44HL184709
Award Date 8/10/26
Completion Date 7/31/29
Dollars Obligated $3M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Webster, TX, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Perfusion Solutions Inc. $217,013 on August 1, 2026, to develop a bearingless, fail-safe pump for patients with single ventricle physiology following Fontan surgical palliation under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds Phase I research to design and develop a bearingless motor integrated into a centrifugal pump rotor, with the pump's stator incorporating the motor stator. The device is engineered to...
- Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- The National Heart, Lung, and Blood Institute awarded Lazarus 3D, Inc. $400,016 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate PRE-SURE-CHD, a patient-specific preoperative surgical rehearsal and planning platform for congenital heart defects using 3D printing technology. The project develops synthetic materials that replicate the mechanical properties of cardiac tissue, creates patient-specific 3D-printed prototypes informed by CT...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $115,584 on July 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support computational and experimental investigations of deformation-driven molecular pathways in single right ventricle congenital heart disease. The project, a K25 career development award, will fund research into tricuspid valve regurgitation in pediatric patients with single right ventricle congenital heart...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $857,878 for a Project Grant (R01HL188153) on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development and evaluation of pediatric cardiac foundation models—machine learning models pre-trained on large volumes of unlabeled electrocardiogram (ECG), echocardiogram (ECHO), chest X-ray, and clinical text...